A recent study indicates that patients who stop using blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who end conventional lifestyle plans.
Published data in a major medical journal shows that while obese individuals can lose about a fifth of their body weight while using the jabs, the mass comes back at an estimated rate of 0.8 kg per month after stopping.
"People buying such treatments should be cognizant of the risk of quick weight regain when the therapy is stopped," stated expert Dr. Susan Jebb.
That rate of regain suggests a return to pre-treatment weight in about one and a half years.
Weighing Treatments
The study, which examined 37 of trials involving over 9,000 of participants, contrasted the outcomes of these new drugs with older methods.
The team point out that individuals who shed pounds through diet and exercise generally have a slower creep back—perhaps 100 grams monthly—once they finish.
The Reason for the Rapid Regain
Nutrition scientists believe the mode of action of the injections is key to understanding the amplified weight return.
The injections mimic a natural hormone called GLP-1, which controls feelings of fullness.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production might result in the body to produce less of its own natural hormone, and could diminish sensitivity to its effects," said Dr. Adam Collins, a nutrition expert.
"Stopping of this medication leads to appetite is unsuppressed, making excessive eating far more likely."
A Chronic Condition?
The NHS advise the jabs for people with obesity-related health risks, accompanied by prescribed lifestyle changes.
Many experts contend that, due to the high risk of relapse, the therapy should be considered life-long.
This perspective is echoed by pharmaceutical companies, who say that the results "underscore the persistent character of excess weight," comparing it to managing diseases like high blood pressure.
User Accounts
Users who have come off the medication describe a powerful return of hunger.
"It was like something flipping and I was suddenly starving," recalled one woman.
This challenge is exacerbated if users have not developed permanent lifestyle or habit modifications during treatment.
Significant Adoption
Figures suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.
- Use is greater among females compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
In conclusion, researchers caution that while these medications are effective tools for shedding pounds, they are not a standalone fix and maintained weight loss relies on combined behavioural management.
